1,180
Participants
Start Date
March 31, 2016
Primary Completion Date
July 31, 2016
Study Completion Date
July 31, 2016
GSP 301 NS
FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
Olopatadine HCl NS
2 sprays in each nostril twice daily for 14 days
Mometasone furoate NS
2 sprays in each nostril twice daily for 14 days
GSP 301 Placebo NS
2 sprays in each nostril twice daily for 14 days
Investigational Site 20, Mission Viejo
Investigational Site 31, San Diego
Investigational Site 29, San Jose
Investigational Site 25, Centennial
Investigational Site 22, Colorado Springs
Investigational Site 10, Jupiter
Investigational Site 30, Miami
Investigational Site 37, Marietta
Investigational Site 15, Stockbridge
Investigational Site 23, Stockbridge
Investigational Site 11, Louisville
Investigational Site 14, Baltimore
Investigational Site 33, Wheaton
Investigational Site 26, Ypsilanti
Investigational Site 19, Minneapolis
Investigational Site 21, St Louis
Investigational Site 16, Bellevue
Investigational Site 12, Skillman
Investigational Site 36, Rochester
Investigational Site 18, Raleigh
Investigational Site 27, Cincinnati
Investigational Site 34, Middleburg Heights
Investigational Site 32, Medford
Investigational Site 35, Portland
Investigational Site 13, Orangeburg
Investigational Site 17, Spartanburg
Investigational Site 3, Austin
Investigational Site 5, Austin
Investigational Site 8, Austin
Investigational Site 1, Kerrville
Investigational Site 7, New Braunfels
Investigational Site 2, San Antonio
Investigational Site 4, San Antonio
Investigational Site 6, San Antonio
Investigational Site 9, San Antonio
Investigational Site 28, Waco
Investigational Site 24, Draper
Glenmark Specialty S.A.
INDUSTRY